Today: 8 June 2026
Agilysys Shares Rise After Earnings Beat
19 May 2026
2 mins read

Agilysys Shares Rise After Earnings Beat

NEW YORK, May 18, 2026, 19:06 EDT

  • Agilysys shares rose 16.7% to $81.90 in after-hours trading. The stock had ended the regular session at $70.20.
  • Agilysys reported revenue of $82.9 million for its fiscal fourth quarter and set its fiscal 2027 revenue outlook in a range of $365 million to $370 million.
  • The move was notable with tech stocks weaker, as the Nasdaq slipped 0.5% late.

Agilysys Inc. shares jumped in late trading Monday as the hospitality software company posted record fiscal Q4 revenue and issued a fiscal 2027 outlook ahead of its most recent annual sales figure.

Agy stock was last at $81.90 in after-hours trading at 7:00 p.m. ET, up $11.70 from the close, after earlier reaching $82.95. Shares had climbed 4.3% in the regular session to settle at $70.20.

Agilysys shares had been stuck below their 52-week high of $145.25, even as software stocks with solid subscription revenue stayed in focus for investors. Tech stocks broadly slipped on Monday, with the Nasdaq falling 0.51% and the S&P 500 edging down 0.07%, according to Investing.com data.

Agilysys reported total net revenue of $82.9 million for the quarter ended March 31, up 11.7% from $74.3 million last year. Net income came in at $12.3 million, or 43 cents per diluted share, up from $3.9 million, or 14 cents, in the year-ago period.

Adjusted diluted earnings came in at 63 cents per share, beating the analyst estimate by 13 cents, according to Investing.com. Revenue also beat consensus, coming in above $81.56 million.

Recurring revenue stood out for investors, with Agilysys reporting a record $54.4 million for the quarter. That made up 65.5% of net revenue. Subscription revenue climbed 24.1% from a year ago.

Agilysys CEO Ramesh Srinivasan called it the company’s 17th straight record revenue quarter, adding that subscription sales should keep driving growth in fiscal 2027. The company is leaning into new AI-native software modules, including revenue intelligence and central reservation system products, as it expands its offerings.

Agilysys is guiding for fiscal 2027 revenue of $365 million to $370 million, and says subscription revenue should jump at least 30%. The company expects adjusted EBITDA to reach 24% of revenue, up from 21.2% in fiscal 2026. Adjusted EBITDA is operating profit before interest, tax and certain non-cash charges.

Agilysys CFO Dave Wood called fiscal 2026 a “record-breaking year” as sales momentum continued into the new year. Full-year revenue for fiscal 2026 was up 15.9% at $319.3 million, with free cash flow increasing to $68.1 million. Business Wire

Competitive comparisons are tight but worth noting. Agilysys makes hospitality software such as property management and POS. Oracle Hospitality has hotel property-management and POS offerings, and PAR Technology focuses on POS and management software for restaurants.

Agilysys revenue came in 1.7% ahead of Wall Street targets, according to StockStory. The company’s fiscal 2027 revenue outlook at the midpoint was 1.1% over analyst consensus. Shares rose 11% just after the report, StockStory said.

After-hours gains may not all stick once the regular session opens. Trading outside normal hours often sees thinner volume and wider spreads. Agilysys pointed to risks with the broader economy and said continuing sales trends and getting more from AI could be tough.

Agilysys put out its fiscal Q4 webcast at 4:30 p.m. ET Monday. A replay is up now on the company’s investor events page.

Stock Market Today

  • Markets React as 100 Days of Middle East Conflict Unfold; Delta Eyes Trans-Pacific Expansion
    June 8, 2026, 9:15 AM EDT. After 100 days of war in the Middle East, renewed Israeli-Iranian strikes threaten the fragile ceasefire, roiling global markets. President Trump called for an immediate ceasefire, reflecting tensions between Iran, Israel, and the U.S. In aviation, Delta Air Lines aims to narrow the trans-Pacific profit gap with United, targeting leadership in long-haul flights-a lucrative sector. Delta reported $2.79 billion in trans-Pacific profits last year, versus United's $6.89 billion. Meanwhile, Italian coffee firm Lavazza is entering the U.S. single-serve market with espresso tablets, challenging Keurig Dr Pepper's dominance amid rising North American sales.

Latest articles

Plug Power Stock Faces a Make-or-Break Week After Friday’s 10% Drop

Plug Power Stock Faces a Make-or-Break Week After Friday’s 10% Drop

8 June 2026
Plug Power rose 2.95% to $3.31 in Monday pre-market trading after a $39.2 million federal tax credit sale tied to its St. Gabriel hydrogen facility, as investors await CEO Jose Luis Crespo’s June 11 update on liquidity and asset sales amid ongoing losses and a recent 10.69% stock drop.
ABAT Shares Jump on DOE’s $115M Lithium Grant Return

ABAT Shares Jump on DOE’s $115M Lithium Grant Return

8 June 2026
American Battery Technology Co shares soared 29.58% to $4.03 premarket after the U.S. Department of Energy fully reinstated a $115 million grant for its Nevada lithium refinery, restoring federal funding for the Tonopah Flats Lithium Project with no change to awarded funds or milestones, though risks remain from permitting, financing, and volatile lithium prices.
NANO Nuclear Stock Bounces, Investors Eye What’s Next

NANO Nuclear Stock Bounces, Investors Eye What’s Next

8 June 2026
NANO Nuclear Energy jumped 7.8% to $25.40 in premarket trading after a 9.9% Friday drop, as traders weighed fresh insider sales filings and recent regulatory progress on its KRONOS microreactor project; the company held $568.7 million in cash as of March 31, but faces sector-wide volatility and execution risks.
Nurix Shares Jump Premarket on Roche $2.3 Billion Cancer Drug Deal

Nurix Shares Jump Premarket on Roche $2.3 Billion Cancer Drug Deal

8 June 2026
Nurix soared 20.4% to $17.62 premarket after Roche agreed to pay $700 million up front in a bexobrutideg collaboration worth up to $2.3 billion, a major cash boost and external validation for Nurix’s lead blood cancer drug ahead of a planned Phase 3 trial, with Roche’s clinical and commercial backing now in play.
ServiceNow Jumps After Wall Street Shifts AI View
Previous Story

ServiceNow Jumps After Wall Street Shifts AI View

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz
Next Story

US Stock Market Today: Live Updates 19.05.2026

Go toTop